Aristotle University Of Thessaloniki (AUTH)
Η επίδραση των αναστολέων της διπεπτυδυλπεπτιδάσης 4 στη λειτουργία του ενδοθηλίου και στην ελαστικότητα της αορτής σε διαβητικούς τύπου 2
Abstract
dc:descriptionThe purpose of this study was to evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor, vildagliptin, on endothelial function and arterial stiffness (AS) in patients with type 2 diabetes (Τ2DM). Sixty-four drug-naive diabetic patients, with inadequate glycemic control, participated in this randomized, open-label study. Half of the patients received metformin 1700 mg/day and the other half of them received metformin 1700 mg/day plus vildagliptin 100 mg/day for 6 months. AS was measured by carotid-femoral pulse wave velocity (cfPWV), and endothelial function by asymmetric dimethylarginine (ADMA) levels. Body weight (BW), body mass index (BMI), blood pressure (BP), ADMA, hsCRP, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), lipid profile, albumin/creatinine ratio (A/CR), fasting insulin, c-peptide, homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) were also assessed at baseline and after 6 months. We found that vildagliptin in combination with metformin had a beneficial influence on ADMA, hs-CRP, HbA1c, C-peptide and HOMA-β index (p <0,05) but had no effect on cfPWV, BP, BW, BMI, lipid profile, A/CR and HOMA-IR compared with metformin alone (p=NS). In conclusion, the addition of vildagliptin to metformin for a period of six months seems to improve endothelial function, glycemic control and β-cell function but has no effect on AS in drug-naive patients with Τ2DM.The purpose of this study was to evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor, vildagliptin, on endothelial function and arterial stiffness (AS) in patients with type 2 diabetes (Τ2DM). Sixty-four drug-naive diabetic patients, with inadequate glycemic control, participated in this randomized, open-label study. Half of the patients received metformin 1700 mg/day and the other half of them received metformin 1700 mg/day plus vildagliptin 100 mg/day for 6 months. AS was measured by carotid-femoral pulse wave velocity (cfPWV), and endothelial function by asymmetric dimethylarginine (ADMA) levels. Body weight (BW), body mass index (BMI), blood pressure (BP), ADMA, hsCRP, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), lipid profile, albumin/creatinine ratio (A/CR), fasting insulin, c-peptide, homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) were also assessed at baseline and after 6 months. We found that vildagliptin in combination with metformin had a beneficial influence on ADMA, hs-CRP, HbA1c, C-peptide and HOMA-β index (p <0,05) but had no effect on cfPWV, BP, BW, BMI, lipid profile, A/CR and HOMA-IR compared with metformin alone (p=NS). In conclusion, the addition of vildagliptin to metformin for a period of six months seems to improve endothelial function, glycemic control and β-cell function but has no effect on AS in drug-naive patients with Τ2DM.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zografou, Ioanna
- Ζωγράφου, Ιωάννα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39123